MARKET

LIFE

LIFE

Atyr Pharma Inc
NASDAQ
1.270
-0.030
-2.31%
After Hours: 1.270 0 0.00% 17:25 12/01 EST
OPEN
1.290
PREV CLOSE
1.300
HIGH
1.320
LOW
1.220
VOLUME
187.70K
TURNOVER
0
52 WEEK HIGH
2.700
52 WEEK LOW
1.080
MARKET CAP
74.37M
P/E (TTM)
-1.3188
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LIFE last week (1120-1124)?
Weekly Report · 6d ago
aTyr Pharma (LIFE) Gets a Hold from Oppenheimer
TipRanks · 11/22 12:55
Atyr Pharma Inc: Notice of Effectiveness
Press release · 11/21 17:06
Weekly Report: what happened at LIFE last week (1113-1117)?
Weekly Report · 11/20 10:17
Promising Potential of aTyr Pharma’s Efzofitimod in Treating Rheumatoid Arthritis and Associated Lung Disease Underpins Buy Rating
Atyr pharma’s drug, efzofitimod, has promise in treating rheumatoid arthritis and lung disease. Joseph pantginis, an analyst from h.c. Wainwright, has reiterated the buy rating on the stock. Atyr has a price target of $35.00.
TipRanks · 11/14 11:26
Atyr Pharma Inc: Statement of changes in beneficial ownership of securities
Press release · 11/14 00:43
aTyr Pharma Presents Poster Demonstrating Preclinical Effects Of Efzofitimod In Rheumatoid Arthritis And Rheumatoid Arthritis-Associated ILD At The ACR Convergence 2023
Atyr pharma announces a poster presentation for its lead therapeutic candidate, efzofitimod, at the american college of rheumatology convergence 2023. Atyr is a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease. The poster presents findings from preclinical models of rheumatoid arthritis and ra-associated ild.
Benzinga · 11/13 13:28
aTyr Pharma files for $300M mixed-shelf offering
Atyr pharma has filed for a $300m mixed-shelf offering. The company may also offer securities as may be issuable. The prospectus is not an offer to sell the securities. Healthcare atyr pharmaceutical files for $300 million offering of common stock.
Seeking Alpha · 11/13 12:24
More
About LIFE
aTyr Pharma, Inc. is a biotherapeutics company engaged in the discovery and development of medicines from its tRNA synthetase platform. The Company’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. The Company’s primary focus is efzofitimod, a clinical-stage product candidate, which targets neuropilin-2 (NRP2) to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a mechanism of action for potentially treating lung inflammation and fibrosis. Its lead indication for efzofitimod is pulmonary sarcoidosis, a major form of interstitial lung disease. Its other product candidates include ATYR2810, NRP2 mAbs, AARS and DARS. ATYR2810 is a product candidate from its NRP2 antibody program. It is also advancing its preclinical pipeline of tRNA synthetases and NRP2. It has also advanced its preclinical pipeline of NRP2 targeting antibody candidates.

Webull offers aTyr Pharma Inc stock information, including NASDAQ: LIFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIFE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LIFE stock methods without spending real money on the virtual paper trading platform.